Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: People living with human immunodeficiency virus (HIV; PLHIV) on antiretroviral therapy (ART) are still at risk of pneumococcal disease and have over 2-fold higher pneumococcal carriage prevalence than HIV-uninfected (HIV-) adults). Carriage is a risk factor for pneumococcal disease, antimicrobial resistance (AMR) emergence, and transmission. Therefore, we tested whether the high prevalence of pneumococcal carriage in PLHIV on ART is associated with increased bacterial density, shedding, and AMR.

Methods: We recruited asymptomatic PLHIV on ART for >1 year (PLHIV-ART>1y) and HIV- adults. Nasopharyngeal swab samples were collected on days 3, 7, 14, 21, and 28, followed by monthly collections for 12 months, while shedding samples were collected on days 3, 21, and 28. Peripheral blood samples were collected on day 3 to measure CD4 cell count and HIV viral load. Pneumococcal carriage density and shedding were assessed using standard bacterial culture, multiple carriage was detected using whole-plate sweep sequencing, and AMR profiling was conducted using disk diffusion and Etest.

Results: PLHIV-ART>1y had a higher propensity for high-density carriage (adjusted odds ratio, 1.67 [95% confidence interval (CI), 1.07-2.60]; = .02). Moreover, PLHIV-ART>1y are more likely to shed pneumococci than HIV- adults (adjusted odds ratio, 2.52 [95% CI, 1.06-6.00]; = .04), with carriage density identified as an important risk factor for shedding (3.35 [1.55-7.24]; = .002). Aerosol shed isolates from PLHIV-ART>1y were mostly multidrug resistant (18 of 29 [ 62%; 95% CI, 48%-77%]).

Conclusions: These findings indicate that PLHIV-ART>1y remain at high risk of pneumococcal disease and could also be an important reservoir for shedding multidrug-resistant pneumococci.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343114PMC
http://dx.doi.org/10.1093/ofid/ofaf422DOI Listing

Publication Analysis

Top Keywords

pneumococcal disease
12
pneumococcal carriage
12
hiv- adults
12
samples collected
12
antiretroviral therapy
8
risk pneumococcal
8
risk factor
8
plhiv art
8
density shedding
8
collected days
8

Similar Publications

Overview: We analysed Australian Immunisation Register (AIR) data, predominantly for National Immunisation Program funded vaccines, as at 2 April 2023 for children, adolescents and adults, focusing on the calendar year 2022 and on trends from previous years. This report aims to provide comprehensive analysis and interpretation of vaccination coverage data to inform immunisation policy and programs.

Children: Fully vaccinated coverage in Australian children in 2022 was 0.

View Article and Find Full Text PDF

remains a leading respiratory pathogen for children and the elderly. In Taiwan, a national PCV13 catch-up vaccination programme for children began in March 2013. This study investigates the population structure and antimicrobial profiles of pneumococcal isolates in Taiwan from 2006 to 2022.

View Article and Find Full Text PDF

Vaccine Immunity Against Pneumococcus in Children With Sickle Cell Disease: A Retrospective Single-center Study.

Pediatr Infect Dis J

September 2025

Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Unit of Immunology, Vaccinology, and Rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Background And Aims: Sickle cell disease (SCD) patients are at a higher risk of pneumococcal invasive diseases. Vaccination is the central strategy for protecting these children, along with penicillin prophylaxis. However, it is unclear how often these children should be revaccinated with pneumococcal vaccines.

View Article and Find Full Text PDF

causes otitis media and severe diseases including pneumonia, meningitis and bacteraemia. The rise of antimicrobial resistance (AMR) in , facilitated by mobile genetic elements (MGEs), complicates infection treatment. While pneumococcal conjugate vaccine (PCV) deployment has reduced disease burden, non-vaccine serotypes (NVTs) have increased and now cause invasive disease.

View Article and Find Full Text PDF

Background: SLE has increased risk of invasive pneumococcal disease due to immune dysregulation and immunosuppression. European Alliance of Associations for Rheumatology recommendations suggest sequential vaccination with conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, data on immunogenicity of sequential vaccination in SLE are limited.

View Article and Find Full Text PDF